|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In order to explore the application value of DCE-MRI in clinical diagnosis and treatment, guide early clinical diagnosis, evaluate prognosis, guide clinical selection of treatment options and improve medical level, the expression of adenocarcinoma, its relationship with clinicopathology, and the significance of co-expression of the proliferating cell nuclear antigen (PCNA), Ki67 protein and cyclooxygenase 2 (COX-2) in breast cancer are analyzed.
|
31289003 |
2019 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Long-term COX-2 inhibition markedly reduced adenocarcinoma formation, as well as angiogenesis in a mouse model of prostate-specific PKCε expression and Pten loss.
|
29765153 |
2018 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Interestingly, moderate immunoreactivity for ANXA1 and FPR1 but increased immunolabeling for COX-2 were observed in Barrett́s esophagus and esophageal adenocarcinomas.
|
29254791 |
2018 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
The expression of the HSD17B12, ELOVL5, and COX-2 enzymes increased according to the grade of the endometrioid ovarian adenocarcinomas.
|
29324448 |
2018 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We examined the association between COX-2 and DCAMKL1 expression in gastric carcinomas in clinical samples (early gastric well-differentiated adenocarcinoma) and Cdx2-transgenic mice; and the DCAMKL1-transgenic mouse stomach using immunohistochemistry and quantitative real-time polymerase chain reaction.
|
25228975 |
2014 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
The aim of this study was to evaluate cyclooxygenase-2 (COX-2) immunoreactivity in colorectal adenocarcinomas and to find correlations with different pathological features.
|
25169526 |
2014 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We evaluated how COX-2 overexpression affected overall postoperative survival in pancreatic head adenocarcinomas.
|
24950702 |
2014 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
The purpose of our study was to characterize the molecular profile of AA and explore the role of targeted therapy against cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR).
|
24149137 |
2013 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Fresh tissue samples from 37 patients with colorectal adenocarcinomas were analyzed for MAGE and SSX mRNA by reverse transcription-polymerase chain reaction (RT-PCR) and their paraffin-embedded tissues were used for immunohistochemistry for cyclooxygenase 2 (COX2), vascular endothelial growth factor (VEGF), and survivin.
|
22287745 |
2012 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
There was also a higher prevalence of microsatellite instability-high tumours and low Cox-2 expression in colorectal SRCC as opposed to conventional adenocarcinoma.
|
20686774 |
2011 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Our data suggest that in addition to COX-2, EP2 and EP4 receptors could be a selective target in the prevention and/or treatment of the Barrett's-associated adenocarcinoma.
|
19843025 |
2010 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
COX-2, the inducible isoenzyme, was found to be overexpressed in approximately 85% of colorectal adenocarcinomas, contributing to key steps in tumor development.
|
20075740 |
2010 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >or= 10 each group) using qRTPCR, single and double immunohistochemistry.
|
19758455 |
2009 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrated that p-Akt and COX-2 were overexpressed in gastric adenocarcinomas and their expression levels were elevated with the ascending order of tumor malignancy; rAd5-A+C targeting COX-2 and Akt1 downregulated their expression significantly in a sequence-specific manner, exerting inhibitory effects on SGC7901 and U251 cell proliferation, invasion and apoptosis.
|
19925030 |
2009 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Regardless of serration, COX-2 overexpression was frequent (approximately 85%) in colorectal adenocarcinomas.
|
18230181 |
2008 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Moreover, immunohistochemical analysis using serial sections of human colon adenocarcinomas revealed a strong positive correlation between COX-2 and FasL (r=0.722; P<0.0001) expression, and between EP1 receptor and FasL (r=0.740; P<0.0001) expression, in the tumour cells.
|
18648368 |
2008 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India.
|
18330937 |
2008 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Regardless of serration, COX-2 overexpression was frequent (approximately 85%) in colorectal adenocarcinomas.
|
18230181 |
2008 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
We studied in mice and human adenocarcinoma-derived Caco-2 cells the impact of low calcium on markers of inflammation (cyclooxygenase-2; COX-2), of detoxification (pregnane and xenobiotic receptor (PXR)/steroid and xenobiotic receptor (SXR), cytochrome P450 steroid-inducible 3a11 (CYP3A11)), and on expression of the vitamin D system as a protection against tumorigenesis.
|
18327873 |
2008 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase (COX)-2 appears to play an important role in gastrointestinal carcinogenesis, and COX-2 overexpression has been demonstrated both in esophageal adenocarcinomas and lymph nodes metastasis.
|
18443952 |
2008 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
|
18349295 |
2008 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C).
|
18094611 |
2008 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
LHGDN |
We evaluated the prognostic significance of COX-2 expression in pancreatic adenocarcinomas.
|
18000398 |
2007 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
RGD |
COX-2 may play an important role in esophageal carcinogenesis through the activation of the inflammation-metaplasia-adenocarcinoma sequence.
|
17675820 |
2007 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
|
17581270 |
2007 |